2545 completed, 650 terminated, 567 recruiting, 390 unknown. 4827 Phase 1, 1613 Phase 2.
Follow Skin Diseases: new trials by email Literature Review of Skin Diseases trials Research Report on Skin Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Epidermal Growth Factor Receptor Inhibition for Keratinopathies Erlotinib - Epidermolytic Ichthyosis, Palmoplantar Keratoderma | Phase 1 / Phase 2 | Not yet recruiting | Northwestern University | 44 | 2027-07-01 | 2026-08-03 |
| Combination Immunotherapy Targeting Melanoma Antigen-specific CAR T, CTL and DCvac to treat melanoma. - Melanoma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2027-06-30 | 2026-10-30 |
| Multi-4SCAR-T Therapy Targeting Breast Cancer 4SCAR T cells - Breast Cancer | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 100 | 2027-06-01 | 2026-11-02 |
| Placental Cells for Diabetic Foot Ulcers Placenta Stem Cells - Diabetic Foot Ulcer | Phase 1 | Not yet recruiting | Wake Forest University Health Sciences | 12 | 2027-03-01 | 2026-10-23 |
| C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Systemic Sclerosis (SSc) Refractory to Standard Therapy C-CAR168 - Systemic Sclerosis (SSc), Systemic Sclerosis | Phase 1 | Not yet recruiting | AbelZeta Inc. | 12 | 2027-03-01 | 2026-10-13 |
| Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases Autologous Tumor Infiltrating Lymphocytes, Melphalan, Interleukin-2 - Uveal Melanoma, Metastatic Cutaneous Melanoma | Phase 1 | Not yet recruiting | Vastra Gotaland Region | 6 | 2027-01-31 | 2026-09-09 |
| Regenerative Medicine for Joint Hypermobility and Instability Dextrose 20% Prolotherapy, Autologous Platelet-Rich Plasma, Doxycycline Hyclate Injectable (Investigational) - Ehlers-Danlos Syndrome Hypermobility Type (hEDS), Ehlers-Danlos Syndrome (EDS) | Phase 1 / Phase 2 | Not yet recruiting | Manhattan Pain Medicine, PLLC | 100 | 2027-01-15 | 2026-10-06 |
| Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer Neoadjuvant Chemotherapy, Radiation Therapy, MRI - Breast Cancer, HER2-positive Breast Cancer | Phase 1 / Phase 2 | Not yet recruiting | Ohio State University Comprehensive Cancer Center | 84 | 2027-01-15 | 2026-11-09 |
| HEALTH Trial - Healthy Adult Evaluation of Ivermectin Bioequivalence: Infant Versus Standard Formulation ivermectin infant formula preparation, Standard ivermectin 3mg tablet - Scabies | Phase 1 | Suspended | Murdoch Childrens Research Institute | 52 | 2027-01-01 | 2026-10-09 |
| Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases Trastuzumab Deruxtecan, Stereotactic Radiosurgery - Breast Cancer, HER2-positive Breast Cancer | Phase 1 | Not yet recruiting | Baptist Health South Florida | 20 | 2027-01-01 | 2026-10-01 |
| Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer. BLEX 404 Oral Liquid - Triple Negative Breast Cancer | Phase 1 / Phase 2 | Not yet recruiting | BioLite, Inc. | 44 | 2027-01-01 | 2026-04-13 |
| Locoregional or Systemic Administration of Autologous Tumor Infiltrating Lymphocytes in Patients With Metastatic Melanoma Autologous Tumor Infiltrating Lymphocytes (TIL), Melphalan, Interleukin-2 - Metastatic Uveal Melanoma, Metastatic Cutaneous Melanoma | Phase 1 | Not yet recruiting | Vastra Gotaland Region | 18 | 2027-01-01 | 2026-09-09 |
| HER2 Vaccine for Locally Advanced Breast Cancer HER2 Vaccine - Breast Cancer, HER2-positive Breast Cancer | Phase 1 | Recruiting | Pravin T.P Kaumaya | 36 | 2027-01-01 | 2026-11-05 |
| Study of ACC-1898 in Adult Participants With Advanced Solid Tumors ACC-1898 - Hepatocellular Carcinoma, Renal Cell Carcinoma | Phase 1 | Not yet recruiting | AccSalus Biosciences, Inc. | 40 | 2027-01-01 | 2026-10-28 |
| Neoadjuvant Trastuzumab, Pertuzumab and Zongertinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-5 Study Zongertinib is an orally administered, highly selective, and irreversible HER2-tyrosine kinase inhibitor. - HER2-positive Breast Cancer, Early Breast Cancer (EBC) | Phase 1 | Not yet recruiting | The Netherlands Cancer Institute | 30 | 2027-01-01 | 2026-11-10 |
| An Open-label Phase I/II Safety and Feasibility Basket Study of UKT-CART19.1 CAR-T cells targeting CD19 - Pemphigus Vulgaris (PV), ANCA Associated Vasculitis (AAV) | Phase 1 / Phase 2 | Not yet recruiting | University Hospital Tuebingen | 36 | 2027-01-01 | 2026-11-12 |
| Filsuvez in Infants With Dystrophic or Junctional Epidermolysis Bullosa Filsuvez topical gel: 10% birch triterpenes - Dystrophic Epidermolysis Bullosa, Junctional Epidermolysis Bullosa | Phase 1 | Not yet recruiting | Medical University of South Carolina | 20 | 2027-01-01 | 2026-11-16 |
| Safety and Preliminary Efficacy of HN2302 in Patients With Autoimmune Diseases HN2302 Injection - Autoimmune Disease, Systemic Lupus Erythematosus | Phase 1 | Not yet recruiting | Shenzhen MagicRNA Biotechnology Co., Ltd | 12 | 2026-12-31 | 2026-08-12 |
| Circadian-Optimized Light Therapy for the Treatment of Patients With Advanced Melanoma Receiving Tumor-Infiltrating Lymphocyte Therapy Biospecimen Collection, Internet-Based Intervention, Medical Device Usage and Evaluation - Advanced Cutaneous Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8 | Phase 1 | Not yet recruiting | City of Hope Medical Center | 8 | 2026-12-23 | 2026-06-05 |
| Study of Multiple Ascending Doses (MAD) of M5542 in Participants With Moderate and Severe Eczema M5542 - Eczema | Phase 1 | Not yet recruiting | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 56 | 2026-12-20 | 2026-11-12 |
Showing 20 of 4827. Sign in to see all of them.
Breast Neoplasms (1877) · Melanoma (1215) · Carcinoma, Non-Small-Cell Lung (531) · Triple Negative Breast Neoplasms (463) · Ovarian Neoplasms (412) · Neoplasm Metastasis (350) · Neoplasms (343) · Colorectal Neoplasms (340) · Stomach Neoplasms (262) · Pancreatic Neoplasms (254) · Carcinoma, Renal Cell (241) · Lung Neoplasms (239) · Dermatitis, Atopic (228) · Squamous Cell Carcinoma of Head and Neck (228) · Prostatic Neoplasms (207)
Skin and Connective Tissue Diseases (4825) · Neoplasms by Site (3297) · Neoplasms (3028) · Breast Diseases (2191) · Neoplasms by Histologic Type (1685) · Neoplasms, Nerve Tissue (1285) · Neuroectodermal Tumors (1284) · Neoplasms, Germ Cell and Embryonal (1282) · Neuroendocrine Tumors (1236) · Nevi and Melanomas (1224) · Skin Neoplasms (1200) · Urogenital Diseases (875) · Urogenital Neoplasms (800) · Female Urogenital Diseases and Pregnancy Complications (792)
pembrolizumab (266) · Cyclophosphamide (204) · Paclitaxel (168) · Nivolumab (145) · Trastuzumab (142) · Ipilimumab (111) · Fulvestrant (97) · Carboplatin (89) · Capecitabine (84) · fludarabine (84) · Docetaxel (75) · Interleukin-2 (65) · aldesleukin (63) · palbociclib (58) · Letrozole (54)
National Cancer Institute (NCI) (181) · Pfizer (96) · M.D. Anderson Cancer Center (87) · Novartis Pharmaceuticals (79) · GlaxoSmithKline (77) · Memorial Sloan Kettering Cancer Center (54) · AstraZeneca (46) · Eli Lilly and Company (44) · Hoffmann-La Roche (43) · Mayo Clinic (40) · Bristol-Myers Squibb (38) · H. Lee Moffitt Cancer Center and Research Institute (35) · Sun Pharmaceutical Industries, Inc. (35) · Dana-Farber Cancer Institute (34) · Merck Sharp & Dohme LLC (34)
United States (2889) · China (508) · Spain (348) · Australia (323) · Canada (294) · France (294) · United Kingdom (288) · Germany (249) · South Korea (181) · Italy (170) · Belgium (159) · Japan (150) · Netherlands (135) · Taiwan (96) · Israel (87)
PMID 36648215, PMID 24577748, PMID 30627694, PMID 31401903, PMID 32379297, PMID 32747469, PMID 33011075, PMID 35642432, PMID 40443562, PMID 12473512, PMID 16157940, PMID 16546506, PMID 16758122, PMID 16783576, PMID 17273752, PMID 17906897, PMID 18245541, PMID 18392824, PMID 18536917, PMID 18726994, PMID 19351776, PMID 20113933, PMID 20845479, PMID 21332269, PMID 21730275, PMID 21989902, PMID 22256804, PMID 24765228, PMID 24983357, PMID 25006719, PMID 25144817, PMID 25482871, PMID 25837513, PMID 27484900, PMID 31215818, PMID 31527168, PMID 32350119, PMID 32385714, PMID 32819975, PMID 33795208, PMID 34132224, PMID 34311780, PMID 35234826, PMID 35482127, PMID 36184023, PMID 36457575, PMID 36746511, PMID 36803645, PMID 37082579, PMID 38172595
2023 (62), 2016 (41), 2018 (40), 2019 (38), 2015 (35), 2017 (33), 2014 (31), 2025 (31), 2009 (19), P30CA016672 (16), U01CA062490 (15), UM1CA186709 (15), P30CA015083 (14), P30CA033572 (12), P30CA072720 (10)